Alsabri Mohammed, Elsayed Sarah Makram, Elsnhory Ahmed Bostamy, Abouelmagd Khaled, Ayyad Mohammed, Alqeeq Basel F, Siddiq Abdelmonem, Soliman Yousef, Shahid Muhammad Azan
Pediatrics Emergency Department, St Christopher's Hospital for Children, Philadelphia, PA, USA.
Emergency department, Al, Thawara Modern General Hospital, Sana'a, Yemen.
Pediatr Cardiol. 2024 Jul 30. doi: 10.1007/s00246-024-03606-6.
Pediatric pericarditis presents challenges in its management, necessitating effective therapeutic interventions. Colchicine, known for its efficacy in adults, requires further investigation for its application and safety in pediatric cohorts. A systematic search across renowned databases identified relevant literature on colchicine use in pediatric pericarditis. Twenty-nine articles underwent rigorous screening, with 18 studies meeting inclusion criteria. Data extraction, quality assessment, and synthesis were conducted meticulously. Included studies comprised case reports, case series, and retrospective cohort studies. Colchicine demonstrated efficacy in reducing recurrence rates and symptom burden, with doses ranging from 0.25 mg/day to 2 mg/day. Adverse events were minimal, predominantly gastrointestinal. Notably, nausea was the most common side effect reported. The safety profile of colchicine was favorable, with rare instances of hepatic and hematologic toxicity. Colchicine emerges as a promising therapeutic option for pediatric pericarditis, demonstrating efficacy in reducing recurrence rates and alleviating symptoms. Its favorable safety profile suggests potential as a preferred long-term therapy. However, further research, including randomized controlled trials, is warranted to confirm its efficacy and safety and explore potential combination therapies.
小儿心包炎的治疗具有挑战性,需要有效的治疗干预措施。秋水仙碱在成人中疗效显著,但其在儿科患者中的应用及安全性仍需进一步研究。通过对知名数据库进行系统检索,确定了有关秋水仙碱用于小儿心包炎的相关文献。对29篇文章进行了严格筛选,其中18项研究符合纳入标准。精心进行了数据提取、质量评估和综合分析。纳入的研究包括病例报告、病例系列和回顾性队列研究。秋水仙碱在降低复发率和减轻症状负担方面显示出疗效,剂量范围为0.25毫克/天至2毫克/天。不良事件极少,主要为胃肠道反应。值得注意的是,恶心是报告最多的常见副作用。秋水仙碱的安全性良好,肝毒性和血液学毒性罕见。秋水仙碱是小儿心包炎一种有前景的治疗选择,在降低复发率和缓解症状方面显示出疗效。其良好的安全性表明它有作为首选长期治疗方法的潜力。然而,仍需要进一步研究,包括随机对照试验,以确认其疗效和安全性,并探索潜在的联合治疗方法。